Treatment with iTAC-XS15-CLL01, a novel warehouse-based multi-peptide T-cell activator combined with Toll-like receptor 1/2 ligand XS15, showed preliminary activity and safety in a small cohort of patients with chronic lymphocytic leukemia (CLL), according to data from a phase 1 trial (NCT04688385) published in The Lancet Haematology.1
Peptide-specific IFN-γ T-cell responses occurred in 19 patients (95% CI, 75.1%-99.9%) who received iTAC-XS15-CLL01, with a higher induction of T-cell responses to CLL-related human leukocyte antigen (HLA) class II–restricted peptides from baseline to end of treatment vs class I–restricted peptides. Additionally, T-cell responses were sustained until the end-of-study visit among 84% of patients (n = 16/19), and the rate of T-cell responses to peptides of HLA class I and class II…